Entry into a Material Definitive

On May 7, 2018, AXIM Biotechnologies, Inc. (the Company) enteredintoa Supply Agreement with Noramco, Inc. for the long term purchase of pharmaceutical grade dronabinol. The agreement outlines an initial purchase of the Active Pharmaceutical Ingredient (API) dronabinol, which is a synthetic form of tetrahydrocannabinol (THC), to be used in the Companys clinical trials for treatment of

chemotherapy-induced nausea/vomiting andanorexia associated with weight loss in patients with cancer or AIDS

. The Company intends to microencapsulate the API and formulate it into its proprietary controlled-release chewing gum delivery system, which will go through an open-label bioequivalence study comparing the bioavailability and therapeutic equivalence of the Companys product to th e FDA-approved r

eference listed drug



Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: May 11, 2018


/s/ Dr. George E. Anastassov

Name: Dr. George E. Anastassov

Chief Executive Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

AXIM® Biotechnologies Issues Update Letter to Shareholders - Oct. 28, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19) - Oct. 6, 2020

Auto Refresh